This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2018
ESMO 2018 Kidney Cancer
ESMO 2018
Press Releases
Kidney Cancer
Prostate Cancer
Bladder Cancer
Conferences
Viewing 161-180 of 10957 articles
ASCO GU 2024: Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations
ASCO GU 2024: ASCERTAIN: An Open-Label, Randomized, Phase 1, Window-of-Opportunity Study to Investigate the Biological Effects of Saruparib (AZD5305) and Darolutamide Alone or in Combination in Men with Prostate Cancer Eligible for Radical Prostatectomy
ASCO GU 2024: Differences in Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer Based on Site of Metastasis
ASCO GU 2024: Impact of a Rash Management Guide on Incidence and Severity of Rash with Apalutamide: Experience from the Apa-RP Study in High-Risk Localized Prostate Cancer
ASCO GU 2024: A Convolutional Neural Network Model Using Intraprostatic Patterns of 18F-DCFPyL Uptake in PSMA PET Images to Predict Synchronous Metastases
ASCO GU 2024: Relugolix Versus Leuprolide in Combination with Radiotherapy for Localized Prostate Cancer (REVELUTION Trial): An Initial Analysis of Patient Treatment Preferences and Quality of Life
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
ASCO GU 2024: NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-risk or High-risk Prostate Cancer with BRCA1/2 Gene Alterations
ASCO GU 2024: EMBARK Post Hoc Analysis of Sexual Activity Patient-Reported Outcome Measures
ASCO GU 2024: Clinical and Patient Factors Associated with Treatment Intensification for mHSPC
ASCO GU 2024: Multicentre Prospective Evaluation of Cognitive Function in Patients with Metastatic Castrate-Resistant Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide: The ACE Study
ASCO GU 2024: Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer
ASCO GU 2024: Stockholm3 Validation in a Multi-Ethnic Cohort for Prostate Cancer (SEPTA) Detection: A Multicentered, Prospective Trial
ASCO GU 2024: Preliminary Data from a Dose-escalation Phase 1 Study with HP518, an AR PROTAC Degrader: Safety, Tolerability, Pharmacokinetics, and First Assessment of Anti-tumor Activity in Patients with mCRPC
ASCO GU 2024: Survival and Fracture Risk with Radium-223 Therapy in mCRPC: A Real-World Analysis
ASCO GU 2024: Interim Results from a Phase 1/2 Study of HPN328, a Tri-Specific, Half-Life Extended DLL3-Targeting T-Cell Engager, in Patients with Neuroendocrine Prostate Cancer and Other Neuroendocrine Neoplasms
ASCO GU 2024: Real-world Analyses of Mortality Risk After ADT Initiation in Black vs White Patients with Prostate Cancer
ASCO GU 2024: Real-world Utilization Patterns of Radium-223 in Metastatic Prostate Cancer in the United States: An Administrative Claims Database Study
ASCO GU 2024: Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at Biochemical Recurrence to Predict Subsequent Biochemical Progression-Free Survival in Patients with Prostate Cancer
ASCO GU 2024: Daro-PET: A Phase 2 Trial of Darolutamide as a PSMA Expression Enhancer in Patients with Localized Prostate Cancer
4
5
6
7
8
9
10
11
12
13
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free